Profusa, Inc. $(PFSA)$, a digital health company specializing in continuous biochemical monitoring technology, has announced a Letter of Intent to establish a distribution agreement in Spain for its Lumee Oxygen platform. The agreement is with Dismeval, S.L., a Spanish distributor known for its expertise in medical and surgical equipment across Spain, including the Canary and Balearic Islands. This partnership represents Profusa's initial steps towards building a strong distribution network in Europe. The company aims to introduce its innovative real-time personal healthcare technologies to the clinical community, targeting a $10.5 billion global market for its tissue oxygen technology. This market includes applications in peripheral artery disease, chronic wounds, and critical limb ischemia, addressing a significant clinical need in Europe with over 300,000 endovascular procedures annually.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.